{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:40:24Z","timestamp":1776692424764,"version":"3.51.2"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16K19635."],"award-info":[{"award-number":["JP16K19635."]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The long-term prognosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph\u2009+\u2009ALL) is still unsatisfactory even after the emergence of tyrosine kinase inhibitors (TKIs) against chimeric BCR-ABL, and this is associated with the high incidence of genetic alterations of Ikaros family zinc finger 1 (IKZF1), most frequently the hemi-allelic loss of exons 4\u20137 expressing a dominant-negative isoform Ik6. We found that lenalidomide (LEN), a representative of immunomodulatory drugs (IMiDs), which have been long used for the treatment of multiple myeloma, specifically induced accumulation of Ik6 with the disappearance of functional isoforms within 24\u2009h (i.e., abrupt and complete shut-down of the IKZF1 activity) in Ik6-positive Ph+ALL cells in a neddylation-dependent manner. The functional IKZF3 isoforms expression was also abruptly and markedly downregulated. The LEN treatment specifically suppressed proliferation of Ik6-positive-Ph+ALL cells by inducing cell cycle arrest via downregulation of cyclins D3 and E and CDK2, and of importance, markedly upregulated their apoptosis in synergy with the TKI imatinib (IM). Apoptosis of IM-resistant Ph+ALL cells with T315I mutation of BCR-ABL was also upregulated by LEN in the presence of the newly developed TKI ponatinib. Analyses of flow cytometry, western blot, and oligonucleotide array revealed that apoptosis was caspase-\/p53-dependent and associated with upregulation of pro-apoptotic Bax\/Bim, enhanced dephosphorylation of BCR-ABL\/Akt, and downregulation of oncogenic helicase genes HILLS, CDC6, and MCMs4 and 8. Further, the synergism of LEN with IM was clearly documented as a significant prolongation of survival in the xenograft mice model. Because this synergism was further potentiated in vitro by dexamethasone, a key drug for ALL treatment, the strategy of repositioning IMiDs for the treatment of Ik6-positive Ph+ALL patients certainly shed new light on an outpatient-based treatment option for achieving their long-term durable remission and higher QOL, particularly for those who are not tolerable to intensified therapeutic approaches.<\/jats:p>","DOI":"10.1038\/s41420-021-00523-y","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T06:02:50Z","timestamp":1623391370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform"],"prefix":"10.1038","volume":"7","author":[{"given":"Daisuke","family":"Harama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norie","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minori","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koshi","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Kiyokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abd Aziz","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanji","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"523_CR1","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"2020","unstructured":"Lugo, T. G., Pendergast, A. M., Muller, A. J. & Witte, O. N. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products. Science 247, 1079\u20131082 (2020).","journal-title":"Science"},{"key":"523_CR2","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","volume":"99","author":"B Gleissner","year":"2002","unstructured":"Gleissner, B. et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99, 1536\u20131543 (2002).","journal-title":"Blood"},{"key":"523_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","volume":"18","author":"HM Kantarjian","year":"2000","unstructured":"Kantarjian, H. M. et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J. Clin. Oncol. 18, 547\u2013561 (2000).","journal-title":"J. Clin. Oncol."},{"key":"523_CR4","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/sj.bmt.1705148","volume":"36","author":"M Yanada","year":"2005","unstructured":"Yanada, M. et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transpl. 36, 867\u2013872 (2005).","journal-title":"Bone Marrow Transpl."},{"key":"523_CR5","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/ajh.24137","volume":"90","author":"SN Lim","year":"2015","unstructured":"Lim, S. N. et al. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Am. J. Hematol. 90, 1013\u20131020 (2015).","journal-title":"Am. J. Hematol."},{"key":"523_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3324\/haematol.2014.118588","volume":"100","author":"N Daver","year":"2015","unstructured":"Daver, N. et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 100, 653\u2013661 (2015).","journal-title":"Haematologica"},{"key":"523_CR7","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1200\/JCO.2010.30.1325","volume":"28","author":"M Aric\u00f2","year":"2010","unstructured":"Aric\u00f2, M. et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J. Clin. Oncol. 28, 4755\u20134761 (2010).","journal-title":"J. Clin. Oncol."},{"key":"523_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1074-7613(00)80269-1","volume":"5","author":"JH Wang","year":"1996","unstructured":"Wang, J. H. et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 5, 537\u2013549 (1996).","journal-title":"Immunity"},{"key":"523_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0092-8674(94)90407-3","volume":"79","author":"K Georgopoulos","year":"1994","unstructured":"Georgopoulos, K. et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell 79, 143\u2013156 (1994).","journal-title":"Cell"},{"key":"523_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature06866","volume":"453","author":"CG Mullighan","year":"2008","unstructured":"Mullighan, C. G. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110\u2013114 (2008).","journal-title":"Nature"},{"key":"523_CR11","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/emboj\/16.8.2004","volume":"16","author":"B Morgan","year":"1997","unstructured":"Morgan, B. et al. Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. EMBO J. 16, 2004\u20132013 (1997).","journal-title":"EMBO J."},{"key":"523_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrc1589","volume":"5","author":"R K\u00fcppers","year":"2005","unstructured":"K\u00fcppers, R. Mechanisms of B-cell lymphoma pathogenesis. Nat. Rev. Cancer 5, 251\u2013262 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"523_CR13","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","volume":"126","author":"EC Fink","year":"2015","unstructured":"Fink, E. C. & Ebert, B. L. The novel mechanism of lenalidomide activity. Blood 126, 2366\u20132369 (2015).","journal-title":"Blood"},{"key":"523_CR14","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber, D. M. et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357, 2133\u20132142 (2007).","journal-title":"N. Engl. J. Med."},{"key":"523_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345\u20131350 (2010).","journal-title":"Science"},{"key":"523_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"},{"key":"523_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature 523, 183\u2013188 (2015).","journal-title":"Nature"},{"key":"523_CR18","doi-asserted-by":"publisher","first-page":"9852","DOI":"10.1158\/0008-5472.CAN-07-0105","volume":"67","author":"Y Furuichi","year":"2007","unstructured":"Furuichi, Y. et al. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents. Cancer Res. 67, 9852\u20139861 (2007).","journal-title":"Cancer Res."},{"key":"523_CR19","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1182\/blood-2003-01-0211","volume":"102","author":"X Cao","year":"2003","unstructured":"Cao, X., Deng, X. & May, W. S. Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax. Blood 102, 2605\u20132614 (2003).","journal-title":"Blood"},{"key":"523_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/sj.onc.1202034","volume":"17","author":"DE Wood","year":"1998","unstructured":"Wood, D. E. et al. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene 17, 1069\u20131078 (1998).","journal-title":"Oncogene"},{"key":"523_CR21","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326\u20132335 (2012).","journal-title":"Leukemia"},{"key":"523_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50088-1","volume":"9","author":"MH Robinson","year":"2019","unstructured":"Robinson, M. H. et al. Upregulation of the chromatin remodeler HELLS is mediated by YAP1 in Sonic Hedgehog Medulloblastoma. Sci. Rep. 9, 13611 (2019).","journal-title":"Sci. Rep."},{"key":"523_CR23","doi-asserted-by":"publisher","first-page":"126140","DOI":"10.1172\/jci.insight.126140","volume":"4","author":"G Zhang","year":"2019","unstructured":"Zhang, G. et al. Chromatin remodeler HELLS maintains glioma stem cells through E2F3 and MYC. JCI Insight 4, 126140 (2019).","journal-title":"JCI Insight"},{"key":"523_CR24","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/nsmb1002","volume":"12","author":"C Speck","year":"2005","unstructured":"Speck, C., Chen, Z., Li, H. & Stillman, B. ATPase-dependent cooperative binding of ORC and Cdc6 to origin DNA. Nat. Struct. Mol. Biol. 12, 965\u2013971 (2005).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"523_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8744","volume":"6","author":"KY Lee","year":"2015","unstructured":"Lee, K. Y. et al. MCM8-9 complex promotes resection of double-strand break ends by MRE11-RAD50-NBS1 complex. Nat. Commun. 6, 7744 (2015).","journal-title":"Nat. Commun."},{"key":"523_CR26","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.neo.2019.07.011","volume":"21","author":"MSM Issac","year":"2019","unstructured":"Issac, M. S. M., Yousef, E., Tahir, M. R. & Gaboury, L. A. MCM2, MCM4, and MCM6 in breast cancer: clinical utility in diagnosis and prognosis. Neoplasia 21, 1015\u20131035 (2019).","journal-title":"Neoplasia"},{"key":"523_CR27","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1038\/onc.2017.123","volume":"36","author":"DM He","year":"2017","unstructured":"He, D. M. et al. Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies. Oncogene 36, 3629\u20133639 (2017).","journal-title":"Oncogene"},{"key":"523_CR28","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","volume":"16","author":"E Jabbour","year":"2015","unstructured":"Jabbour, E. et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 16, 1547\u20131555 (2015).","journal-title":"Lancet Oncol."},{"key":"523_CR29","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature21076","volume":"542","author":"LN Chan","year":"2017","unstructured":"Chan, L. N. et al. Metabolic gatekeeper function of B-lymphoid transcription factors. Nature 542, 479\u2013483 (2017).","journal-title":"Nature"},{"key":"523_CR30","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1182\/blood.V128.22.1059.1059","volume":"128","author":"M Huang","year":"2016","unstructured":"Huang, M. et al. Molecular mechanism for synergistic anti-leukemic activity of tyrosine kinase inhibitors and glucocorticoids against Ph+ALL. Blood 128, 1059 (2016).","journal-title":"Blood"},{"key":"523_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2443.2007.01158.x","volume":"13","author":"T Hoshino","year":"2008","unstructured":"Hoshino, T. et al. Reduced BMP4 abundance in Gata2 hypomorphic mutant mice result in uropathies resembling human CAKUT. Genes Cells 13, 159\u2013170 (2008).","journal-title":"Genes Cells"},{"key":"523_CR32","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/cas.13959","volume":"110","author":"N Harada","year":"2019","unstructured":"Harada, N., Hasegawa, A., Hirano, I., Yamamoto, M. & Shimizu, R. GATA2 hypomorphism induces chronic myelomonocytic leukemia in mice. Cancer Sci. 110, 1183\u20131193 (2019).","journal-title":"Cancer Sci."},{"key":"523_CR33","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nm.3936","volume":"21","author":"B Will","year":"2015","unstructured":"Will, B. et al. Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. Nat. Med. 21, 1172\u20131181 (2015).","journal-title":"Nat. Med."},{"key":"523_CR34","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S2352-3026(15)00284-7","volume":"3","author":"M Ogura","year":"2016","unstructured":"Ogura, M. et al. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. Lancet Haematol. 3, e107\u2013e118 (2016).","journal-title":"Lancet Haematol."},{"key":"523_CR35","doi-asserted-by":"publisher","first-page":"e0294","DOI":"10.1097\/MD.0000000000010294","volume":"97","author":"B Lai","year":"2018","unstructured":"Lai, B. et al. Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: a case report. Medicine 97, e0294 (2018).","journal-title":"Medicine"},{"key":"523_CR36","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","volume":"123","author":"AK Fielding","year":"2014","unstructured":"Fielding, A. K. et al. UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123, 843\u2013850 (2014).","journal-title":"Blood"},{"key":"523_CR37","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","volume":"28","author":"R Bassan","year":"2010","unstructured":"Bassan, R. et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09\/00. J. Clin. Oncol. 28, 3644\u20133652 (2010).","journal-title":"J. Clin. Oncol."},{"key":"523_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2009.011221","volume":"95","author":"JM Ribera","year":"2010","unstructured":"Ribera, J. M. et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 95, 87\u201395 (2010).","journal-title":"Haematologica"},{"key":"523_CR39","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbmt.2012.08.021","volume":"19","author":"A Tanguy-Schmidt","year":"2013","unstructured":"Tanguy-Schmidt, A. et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol. Blood Marrow Transpl. 19, 150\u2013155 (2013).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"523_CR40","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M Yanada","year":"2006","unstructured":"Yanada, M. et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL\u2013positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J. Clin. Oncol. 24, 460\u2013466 (2006).","journal-title":"J. Clin. Oncol."},{"key":"523_CR41","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1182\/blood-2009-09-244673","volume":"116","author":"K Hirose","year":"2010","unstructured":"Hirose, K. et al. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19). Blood 116, 962\u2013970 (2010).","journal-title":"Blood"},{"key":"523_CR42","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2002-06-1770","volume":"101","author":"K Uno","year":"2003","unstructured":"Uno, K. et al. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood 101, 3658\u20133667 (2003).","journal-title":"Blood"},{"key":"523_CR43","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1002\/cam4.1323","volume":"7","author":"M Huang","year":"2018","unstructured":"Huang, M. et al. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression. Cancer Med. 7, 1297\u20131316 (2018).","journal-title":"Cancer Med."},{"key":"523_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.leukres.2018.07.022","volume":"72","author":"M Nakamura","year":"2018","unstructured":"Nakamura, M. et al. Notch1 activation enhances proliferation via activation of cdc2 and delays differentiation of myeloid progenitors. Leuk. Res. 72, 34\u201344 (2018).","journal-title":"Leuk. Res."},{"key":"523_CR45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/ejh.12155","volume":"91","author":"K Tokunaga","year":"2013","unstructured":"Tokunaga, K. et al. High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia. Eur. J. Haematol. 91, 201\u2013208 (2013).","journal-title":"Eur. J. Haematol."},{"key":"523_CR46","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1242\/jcs.007344","volume":"120","author":"R Caballero","year":"2007","unstructured":"Caballero, R. et al. Combinatorial effects of splice variants modulate function of Aiolos. J. Cell Sci. 120, 2619\u20132630 (2007).","journal-title":"J. Cell Sci."},{"key":"523_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships, the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 22, 27\u201355 (1984).","journal-title":"Adv. Enzym. Regul."},{"key":"523_CR48","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/sj.leu.2401893","volume":"14","author":"K Iijima","year":"2000","unstructured":"Iijima, K. et al. Expression of thrombopoietin receptor and its functional role in human B-precursor leukemia cells with 11q23 translocation or Philadelphia chromosome. Leukemia 14, 1598\u20131605 (2000).","journal-title":"Leukemia"},{"key":"523_CR49","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1128\/MCB.00740-07","volume":"28","author":"Y Miyagawa","year":"2008","unstructured":"Miyagawa, Y. et al. Inducible expression of chimeric EWS\/ETS proteins confers Ewing\u2019s family tumor-like phenotypes to human mesenchymal progenitor cells. Mol. Cell Biol. 28, 2125\u20132137 (2008).","journal-title":"Mol. Cell Biol."}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-021-00523-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-021-00523-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-021-00523-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T09:41:16Z","timestamp":1669974076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-021-00523-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["523"],"URL":"https:\/\/doi.org\/10.1038\/s41420-021-00523-y","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]},"assertion":[{"value":"2 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"139"}}